EUVIMEDEUVIMED entdecken
Crossref

The cuproptosis-related gene UBE2D2 functions as an immunotherapeutic and prognostic biomarker in pan-cancer

Yao Fei, Danping Cao, Runyu Dong, Yanna Li, Zhixiong Wang, Peng Gao, Menglin Zhu, Xiaoming Wang, Xueliang Zuo, Juan Cai

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03495-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Yao Fei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Ubiquitin-Conjugating Enzymes, Tumor Microenvironment, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Anhui Province, Natural Science Foundation of Anhui Education Department for Distinguished Young Scholars.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorUbiquitin-Conjugating EnzymesTumor MicroenvironmentNeoplasmsHumansPrognosisImmunotherapyFemaleMelanomaKidney NeoplasmsCarcinoma, HepatocellularLiver NeoplasmsUterine Cervical NeoplasmsCTLA-4 AntigenUveal NeoplasmsB7-H1 AntigenUveal Melanoma

Stichwörter der Autor:innen

Anti-tumor drugCuproptosisImmunePan-cancerUBE2D2

Substanzen

Biomarkers, TumorUbiquitin-Conjugating EnzymesCTLA4 protein, humanCTLA-4 AntigenCD274 protein, humanB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu, China.
  • Department of Hepatobiliary Surgery, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu, China.
  • Department of Gastrointestinal Surgery, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu, China. zuoxueliang0202@126.com.
  • Anhui Province Key Laboratory of Non-Coding RNA Basic and Clinical Transformation, Wannan Medical College, Wuhu, China. zuoxueliang0202@126.com.
  • Anhui Province Key Laboratory of Non-Coding RNA Basic and Clinical Transformation, Wannan Medical College, Wuhu, China. caijuan1987@yeah.net.
  • Department of Oncology, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu, China. caijuan1987@yeah.net.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Anhui Province
  • Natural Science Foundation of Anhui Education Department for Distinguished Young Scholars
  • Natural Science Foundation of Anhui Education Department for Excellent Young Scholars
  • Support Plan for Outstanding Young Talents of Anhui Education Department
  • Key Research and Development Project of Anhui Province
  • the Science and Technology Project of Wuhu City
  • Talent Introduction Science Foundation of Yijishan Hospital, Wannan Medical College

Zitieren

APA

Fei, Y., Cao, D., Dong, R., Li, Y., Wang, Z., Gao, P., Zhu, M., Wang, X., Zuo, X., & Cai, J. (2024). The cuproptosis-related gene UBE2D2 functions as an immunotherapeutic and prognostic biomarker in pan-cancer. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03495-4

Vancouver

Fei Y, Cao D, Dong R, Li Y, Wang Z, Gao P, et al. The cuproptosis-related gene UBE2D2 functions as an immunotherapeutic and prognostic biomarker in pan-cancer. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03495-4

BibTeX
@article{Fei2024,
  author = {Fei, Yao and Cao, Danping and Dong, Runyu and Li, Yanna and Wang, Zhixiong and Gao, Peng and Zhu, Menglin and Wang, Xiaoming and Zuo, Xueliang and Cai, Juan},
  title = {The cuproptosis-related gene UBE2D2 functions as an immunotherapeutic and prognostic biomarker in pan-cancer},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03495-4}
}
Kostenlos starten →